Article ID Journal Published Year Pages File Type
5693756 The Breast 2017 6 Pages PDF
Abstract
Surprisingly little is known of survival beyond the median for HER2-positive MBC. Longer trial follow-up is required to help clinicians estimate and explain the best-case scenario. Simple multiples of the median OS provide a reasonable framework for estimating then explaining survival times to patients.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Obstetrics, Gynecology and Women's Health
Preview
More than just the median: Calculating survival times for patients with HER2 positive, metastatic breast cancer using data from recent randomised trials
Authors
, , , , ,